Arrowhead Research Corp. (ARWR) Reports In-Line Q3 EPS, Provides Update on ARC-520
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Arrowhead Research (ARWR) Sees Early Upside
August 14, 2014 9:44 AM EDTArrowhead Research (NASDAQ: ARWR) seeing strong morning upside on solid volume. Shares are up 7%.
Deutsche Bank Maintains Buy Rating on Arrowhead Research (ARWR)
August 13, 2014 9:58 AM EDTDeutsche Bank maintained a Buy rating on Arrowhead Research (NASDAQ: ARWR) with a price target of $45. Comments follow its ARC-520 update.
Analyst Alethia Young said, "We feel more confident in ARC-520 and their platform technology after this interim update. Safety looks solid... More
Arrowhead Research (ARWR) Bullish Stance Reiterated at Jefferies as ARC-520 Shows Highly Encouraging Efficacy
August 13, 2014 6:52 AM EDTJefferies analyst Thomas Wei reiterated a Buy rating and $30 price target on Arrowhead Research (NASDAQ: ARWR) as ARC-520 shows highly encouraging efficacy.
Wei commented, "ARWR provided an update from its Phase 2a trial, in which patients receiving a single dose of ARC-520... More
